ストックスクリーナーアプリを入手
22.63
0.09%
-0.02
アフターアワーズ：
22.63
前日終値:
$22.65
開ける：
$22.5
24時間の取引高:
3.10M
Relative Volume:
1.29
時価総額：
$2.86B
収益：
$715.22M
当期純損益:
$-250.10M
株価収益率:
-11.15
EPS:
-2.03
ネットキャッシュフロー:
$-205.58M
1週間 パフォーマンス:
-2.41%
1か月 パフォーマンス:
-17.92%
6か月 パフォーマンス:
+3.48%
1年 パフォーマンス:
-21.53%
1日の値動き範囲:
$22.19
$22.99
1週間の範囲:
$21.07
$23.30
52週間の値動き範囲:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
名前
Apellis Pharmaceuticals Inc
セクター
電話
617-977-5700
住所
100 FIFTH AVENUE, WALTHAM, KY
APLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
22.63 | 2.86B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-26 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-21 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-16 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Neutral |
| 2024-02-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-02 | 開始されました | Mizuho | Neutral |
| 2023-10-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-15 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 繰り返されました | Citigroup | Buy |
| 2023-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-08-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-17 | 再開されました | Stifel | Buy |
| 2022-04-14 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-09-10 | 繰り返されました | Credit Suisse | Neutral |
| 2021-09-10 | 繰り返されました | Needham | Buy |
| 2021-09-10 | 繰り返されました | Oppenheimer | Outperform |
| 2021-09-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-08-19 | 開始されました | Jefferies | Buy |
| 2021-08-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2020-11-19 | 開始されました | Needham | Buy |
| 2020-09-01 | 開始されました | Stifel | Buy |
| 2020-07-20 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-04-01 | 開始されました | Raymond James | Strong Buy |
| 2020-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-11 | アップグレード | Wedbush | Underperform → Neutral |
| 2020-01-07 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-12-19 | 開始されました | BofA/Merrill | Buy |
| 2019-11-22 | 開始されました | Wedbush | Underperform |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-08-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-07-30 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-04-12 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Apellis Pharmaceuticals: Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders - Seeking Alpha
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) - MSN
Volume spikes in Apellis Pharmaceuticals Inc. stock – what they meanJuly 2025 Intraday Action & Long-Term Investment Growth Plans - newser.com
What drives Apellis Pharmaceuticals Inc stock priceInstitutional Buying Trends & Free Exceptional Risk Adjusted Gains - earlytimes.in
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Published on: 2025-09-29 15:38:29 - newser.com
Smart tools for monitoring Apellis Pharmaceuticals Inc.’s price actionJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Using R and stats models for Apellis Pharmaceuticals Inc. forecasting2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com
What MACD and RSI say about Apellis Pharmaceuticals Inc.Market Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Why retail investors pile into Apellis Pharmaceuticals Inc. stockOptions Play & Scalable Portfolio Growth Ideas - newser.com
Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns By Investing.com - Investing.com Nigeria
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know - Benzinga
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) with Low - GuruFocus
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) Amid Com - GuruFocus
Apellis down as Goldman Sachs cuts to sell on risks to outlook - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down After Analyst Downgrade - MarketBeat
Apellis stock cut to sell at Goldman Sachs (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by The Goldman Sachs Group - MarketBeat
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market SessionApellis Pharmaceuticals (NASDAQ:APLS), Concentrix (NASDAQ:CNXC) - Benzinga
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket - Benzinga
Goldman Sachs Downgrades Apellis Pharmaceuticals to Sell From Neutral, Adjusts PT to $18 From $26 - MarketScreener
Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns - Investing.com
Fierce Biotech Layoff Tracker 2025: IO lays off 50% of employees; Heidelberg reduces headcount by 75% - Fierce Biotech
Apellis Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Pallas Capital Advisors LLC Has $949,000 Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Director Sells $713,561.40 in Stock - MarketBeat
Zacks Research Has Bullish Estimate for APLS FY2025 Earnings - MarketBeat
How to monitor Apellis Pharmaceuticals Inc. with trend dashboardsMarket Volume Report & Fast Exit/Entry Strategy Plans - newser.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells $121,700.00 in Stock - MarketBeat
Setup Watch: Should I invest in ATMV before earningsTreasury Yields & Fast Moving Stock Watchlists - khodrobank.com
Dunlop A. Sinclair sells Apellis (APLS) shares worth $713k - Investing.com
Goldman Sachs Group Inc. Has $6.73 Million Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharma director Dunlop sells $713,561 in shares By Investing.com - Investing.com Canada
Apellis Pharma director Dunlop sells $713,561 in shares - Investing.com India
Dunlop A. Sinclair sells Apellis (APLS) shares worth $713k By Investing.com - Investing.com South Africa
Can volume confirm reversal in Apellis Pharmaceuticals Inc.Forecast Cut & Daily Technical Forecast Reports - newser.com
Evaluating Apellis Pharmaceuticals Inc. with trendline analysisJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Stock Market Recap: Will Apellis Pharmaceuticals Inc benefit from rising consumer demand2025 Market Outlook & AI Driven Price Predictions - خودرو بانک
Key resistance and support levels for Apellis Pharmaceuticals Inc.2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - newser.com
Best data tools to analyze Apellis Pharmaceuticals Inc. stockTrade Risk Assessment & Reliable Price Action Trade Plans - newser.com
What is the long term forecast for Apellis Pharmaceuticals Inc stock2025 Trading Recap & Fast Entry High Yield Tips - khodrobank.com
Apellis Pharma VP Chopas sells $4.5k in shares By Investing.com - Investing.com Nigeria
Value Recap: How correlated is Apellis Pharmaceuticals Inc to the S P500July 2025 Breakouts & Community Driven Trade Alerts - خودرو بانک
Woodline Partners LP Grows Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc (APLS) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):